<DOC>
	<DOCNO>NCT00137969</DOCNO>
	<brief_summary>This Phase II/III , randomize , double-blind , placebo-controlled , multicenter study evaluate efficacy safety rituximab compare placebo combine single stable background immunosuppressive medication subject moderate severe systemic lupus erythematosus ( SLE ) . The primary efficacy endpoint trial evaluate 52 week .</brief_summary>
	<brief_title>A Study Evaluate Safety Rituximab Retreatment Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Diagnosis systemic lupus erythematosus ( SLE ) . Active disease screening . Stable use one immunosuppressive drug . Use antimalarial drug . For subject reproductive potential ( male female ) , use reliable mean contraception throughout study participation . Unstable patient thrombocytopenia experience high risk develop clinically significant bleed organ dysfunction require therapy plasmapheresis acute blood platelet transfusion . Active moderate severe glomerulonephritis . Retinitis , poorly control seizure disorder , acute confusional state , myelitis , stroke stroke syndrome , cerebellar ataxia , dementia currently active result SLE . Lack peripheral venous access . Pregnant woman nurse ( breast feeding ) mother . History severe , allergic , anaphylactic reaction humanize murine monoclonal antibody . Significant , uncontrolled medical disease organ system related SLE investigator 's opinion would preclude subject participation . Concomitant condition require oral systemic corticosteroid use . Known human immunodeficiency virus ( HIV ) infection . Known active infection kind ( exclude fungal infection nail bed ) major episode infection require hospitalization treatment intravenous ( IV ) antibiotic . History deep space infection . History serious recurrent chronic infection . History cancer , include solid tumor , hematological malignancy , carcinoma situ . Active alcohol drug abuse , history alcohol drug abuse . Major surgery . Previous treatment CAMPATH1H antibody . Previous treatment B celltargeted therapy . Treatment investigational agent within 28 day screen ( Day 7 ) 5 halflives investigational drug ( whichever longer ) . Receipt live vaccine within 28 day prior screen . Intolerance contraindication oral IV corticosteroid . Use new immunosuppressive drug prior screen change dose ongoing immunosuppressive drug prior screen . Prednisone dose â‰¥ 1 mg/kg/day prior screen . Treatment cyclophosphamide calcineurin inhibitor . Treatment second immunosuppressive immunomodulatory drug . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Rituxan</keyword>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
</DOC>